










































































































































































































































Side	Effects:		 Results	 Remission	Rates	 Limitations	 Conclusions	
Ketamine	for	
rapid	reduction	of	
suicidal	ideation:	
a	randomized	
controlled	trial	
Murrough	et	al.	
201512	
Sample	size:	24.	Active	
versus	Placebo:		0.5	
mg/kg	racemic	
ketamine	HCL	or	0.045	
mg/kg	IV	midazolam	
over	40	minutes		
Most	common	side	
effects	of	ketamine	
were	headache,	
dizziness	on	standing,	
anxiety,	poor	
concentration,	poor	
coordination	and	
restlessness	
Assessed	at	24,	48,	72	hours	
and	7	days	post-treatment.	
24	hours	after	treatment	
there	was	no	significant	
difference	in	baseline	SI	
between	groups	(10.8+/-	8.5	
and	14	+/-	10.2	for	ketamine	
and	midazolam)	
At	48	hours	decrease	in	
baseline	suicidal	ideation	
compared	to	the	control	
group	(8.8+/-8.3	and	15.3+/-
10.9	F1,21=4.45,	p=0.047)		
No	statistical	difference	
between	groups	at	72	hours	
and	7	days	
	
Not	available	 Single	dose	of	
ketamine	with	no	
long	term	follow	
up.		
Only	looked	at	
reduction	of	SI	for	
outcomes	
Small	sample	size		
No	data	on	effects	
of	Ketamine	as	
monotherapy	
	
Demonstrated	
tolerability	to	
ketamine	and	
supports	the	data	
that	ketamine	has	
potential	for	rapid	
decrease	in	SI.	More	
studies	needed	to	
study	the	long-term	
effects	of	ketamine.		
A	double-blind,	
randomized,	
placebo-
controlled,	dose-
frequency	study	
of	Intravenous	
ketamine	in	
patients	with	
Treatment-
resistant	
depression	
Singh	et	al.,	
201615	
Sample	size:	67	(45	
women)	ages	18	-64	
years	old.		
Patients	randomized	in	
1	of	4	treatment	
groups:	IV	ketamine	
(0.5mg/kg);	
administrated	2	or	3	
times	weekly	or	IV	
placebo	(0.9%	sodium	
chloride);	administered	
2	or	3	times	weekly.		
Depression	measured	
using	MADRS	=	
Montgomery-Asberg	
Most	common	
treatment	adverse	
events	were	headache,	
anxiety,	dissociation,	
nausea,	and	dizziness	
(most	commonly	on	day	
of	dosing	and	resolved	
within	2	hours)	
	No	deaths	were	
reported,	but	two	
serious	emergent	
adverse	events	
occurred	(unrelated	to	
ketamine);	anxiety	(life	
related)	and	suicide	
Primary	Outcomes:	mean	
baseline	in	MADRS	score	
from	day	1	to	15	improved	in	
both	ketamine	frequency	
groups	(twice	weekly	=	-18.4	
(SD	12)	and	thrice	weekly	=	-
17.7	(SD	7.3)	compared	to	
placebo:	-5.7	(SD	10.2)	and	-
3.1	(SD	5.7)	
Secondary	outcomes:	MADRS	
mean	score	improved	from	
baseline	to	day	29	in	
ketamine	groups	(twice	
weekly	-21.2	(SD	12.9)	and	
thrice	weekly	-21.2	(SD	11.2))	
MADRS	
remission	at	day	
15:	Ketamine	
group	(twice	
weekly	N	=	6;	
37.5%.	thrice	
weekly	N	=	3;	
23.1%)	Placebo	
group	(twice	
weekly	N=	!;	
7.7%	and	thrice	
weekly	N=	0)	
Short	time	period	
assessed	of	4-6	
weeks		
	
No	long-term	
follow-up	
	
Possibility	for	un-
blinding	due	to	
adverse	events	
occurring	in	
treatment	group.		
Short-term	
improvement	in	
depression	is	
possible	with	
ketamine,	even	at	
less	frequent	dosing	
such	as	twice	
weekly.		
Further	studies	are	
needed	to	assess	
long-term	effects	of	
ketamine	and	rates	
of	remission	of	
treatment	resistant	
depression.		
Depression	Rating	Scale	 attempt	on	day	40	–	
more	than	40	weeks	
after	last	dose	
	
versus	placebo	(-4.0	(SD	.1)	
and	-3.6	(SD	6.6))	
Antidepressant	
Efficacy	of	
Ketamine	in	
treatment-
resistant	Major	
depression:	A	two	
site	Randomized	
controlled	trial	
Losifescu	et	al.,	
20134	
	
Sample	size:	72.	Ages	21	
to	80	years	old	with	
primary	diagnosis	of	
MDD	with	treatment	
failure	of	≥	3	
therapeutic	trials.		
	
Randomized	and	
received	either	single	
dose	IV	ketamine	HCL	
(0.5	mg/kg)	or	
midazolam	(0.045	
mg/kg)	infused	over	40	
minutes.		
Ketamine:	most	
common	AE	for	up	to	4	
hours	post-infusion	
were	dizziness,	blurred	
vision,	headache,	
nausea	or	vomiting,	dry	
mouth,	poor	
coordination,	poor	
concentration	and	
restlessness.	
Midazolam:	most	
common	AE	for	same	
time	frame	were	
general	malaise,	
dizziness,	headache,	
restlessness,	nausea	or	
vomiting,	dry	mouth,	
decreased	energy	and	
poor	coordination.		
8/47	ketamine	patients	
reported	dissociative	
symptoms;	which	
resolved	within	2	hours	
post-infusion	
	
Assessed	continuously	for	24	
hours,	then	at	48	hours,	72	
hours	and	7	days	post-
infusion.		
Primary	outcome:	reduction	
in	depression	severity	
assessed	by	MADRS	24	hours	
post-infusion.	Mean	score	
was	lower	in	ketamine	group	
by	7.95	points	(CI	3.20	to	
12.71).		
	
Both	groups	
showed	
worsening	of	
MADRS	score	
each	day	after	
infusion.	
(B=0.0004;	95%	
CI	0.00009	to	
0.00062).	The	
time	to	relapse	
was	measured	
between	4	
midazolam	
responders	and	
21	ketamine	
responders	
which	showed	a	
greater	portion	
of	patients	
without	relapse	
in	the	ketamine	
responder	group	
Single	dose	of	
ketamine	trial;	
unknown	what	
the	effect	would	
be	of	multiple	
dosing	over	the	
same	period	
studied.		
Unknown	long-
term	effects	of	
ketamine	
Study	supports	data	
that	ketamine	
causes	a	rapid	
response	with	only	
one	infusion	as	
monotherapy		
A	Randomized	
Controlled	Trial	of	
Intranasal	
ketamine	in	Major	
Depressive	
disorder	
Lapidus	et	al.,	
20148	
Sample	size	18.	Ages	
21-65	years	old.	Have	
failed	at	least	1	trial	of	
antidepressant	
medication.	Maintained	
standard	treatment	
during	trial.	
Randomized	into	
intranasal	ketamine	HCL	
50mg	and	placebo	
(0.9%	saline	solution)	
and	there	were	two	
treatment	days.		
	
Associated	with	small	
increases	in	psychosis	
and	dissociation,	
systolic	blood	pressure	
increases.		
Most	common	
emergent	AE	were	
feeling	strange	or	
unreal,	poor	memory	
and	weakness	or	fatigue	
–	most	of	these	
symptoms	resolved	
after	4	hours.		
Assessment	occurred	at	40,	
120,	240	minutes,	and	48,	72	
hours	and	7	days.	Symptoms	
improved	after	24	hours	in	
the	treatment	group	
compared	to	the	placebo	(T=	
4.39,	p	<0.001)	with	a	mean	
difference	in	MADRS	score	of	
7.6+/-	3.7	(95%	CI,	3.9-11.3)		
Greatest	effect	
was	seen	at	24	
hours.	MADRS	
scores	were	
similar	in	
ketamine	and	
control	group	at	
7	days.		
Did	not	assess	
Ketamine	as	
monotherapy		
Use	of	non-active	
placebo	with	no	
side	effects	could	
result	in	un-
blinding.		
Small	sample	size	
and	short	study	
time	frame	with	
no	long-term	
effects	measured.		
	
There	were	limited	
AE	and	patients	
who	received	
ketamine	had	a	
favorable	response	
when	evaluated	
using	MADRS.	
Introducing	
intranasal	ketamine	
as	form.	Need	to	
evaluate	long	term	
effects	and	with	
larger	sample	size	
A	Double-Blinded,	
Randomized,	
placebo-
controlled	sub-
dissociative	dose	
Ketamine	pilot	
study	in	the	
treatment	of	
Acute	Depression	
and	Suicidality	in	
a	Military	
Emergency	
Department	
setting	
Burger	et	al.,	
20162	
Sample	size	10.	Ages	18	
to	65	years	old.	
Depression	measured	
using	Beck	Suicidality	
Scale	(BSS),	BHS,	and	
Beck	Depression	
Inventory.	Randomized	
into	ketamine	active	
group	0.2	mg/kg	
infused	over	2	minutes	
and	placebo	group	with	
normal	saline.		
No	depersonalization,	
confusion,	
hallucinations	or	other	
adverse	symptoms	
associated	with	
ketamine	and	no	other	
adverse	effects	were	
noted	by	participants.			
Assessed	before	drug	
administration	and	40,	80,	
120,	and	240	minutes	after	
administration.	BSS	showed	
significant	linear	effects	of	
time	(p	<0.05),	but	not	group	
(p>0.05).	There	was	
significant	linear	time	x	group	
interaction	(p<0.05)	over	the	
4	hour	ED	observation	
period.	BSS	at	follow-up	or	
discharge	was	not	significant	
between	groups.	BHS	showed	
neither	significant	effect	of	
time	or	group,	but	the	time	x	
group	intervention	was	
significant.	BHS	scores	were	
significantly	different	at	
discharge,	but	not	at	follow-
up.		
	
Not	available		 Small	sample	size.		
No	long-term	
effects	on	
remission	
available	or	long-
term	effects	of	
ketamine	use.		
	
Sparse	data	on	
results	and	
statistical	analysis.		
	
Study	was	
terminated	early	
because	of	record-
keeping	trouble.		
Considered	failed	
trial	but	showed	
potential	for	
ketamine	for	acute	
depression	in	the	
ED	setting	with	67%	
of	patients	showing	
a	decrease	in	SI	and	
depression	
symptoms.		
Placebo-
controlled	pilot	
trial	testing	dose	
titration	and	
intravenous,	
intramuscular	and	
subcutaneous	
routes	for	
ketamine	in	
depression	
Loo	et	al.,	201610	
Sample	size:	15	patients	
diagnosed	as	treatment	
refractory	who	received	
ketamine	or	midazolam.	
Ketamine	was	
administered	by	IV,	IM,	
or	SQ	routes	and	dose	
titrated	up	at	0.1	mg/kg	
to	0.4	mg/kg.		
SE	were	observed	at	
higher	doses.	
Symptoms	included:	
depersonalization,	
derealization,	altered	
body	perception	and	
altered	time	perception.	
All	resolved	after	40	
minutes	post-infusion.	
Transient	elevation	
occurred	in	heart	rate,	
systolic	and	diastolic	
blood	pressure.		
Most	common	side	
effects	were	fatigue,	
light-headedness,	
dizziness,	blurred	vision	
and	emotional	lability.		
	
MADRS	was	measured	on	day	
1	of	ketamine	treatment	and	
at	4	hours,	2,	4,	and	7	days	
after	each	treatment.	12	out	
of	15	patients	met	the	
criteria	for	both	response	and	
remission	at	some	point	
during	the	trial.	With	an	
overall	acute	
response/remission	rate	of	
75%	(IV),	60%	(IM)	and	100%	
(SQ).	Mean	time	to	relapse	
was	23.2	days.	There	was	no	
difference	in	MADRS	scores	
between	routes	of	
administration.	Overall,	there	
was	short-term	improvement	
in	both	0.2mg/kg	and	
0.1mg/kg	dosing	versus	
placebo,	although	there	was	
no	linear	trend.			
Placebo	and	
ketamine	groups	
showed	no	
statistical	
difference	at	day	
7	post-
treatment.		
Small	sample	size		
	
Treatment	group	
was	by	sequential	
cohorts	rather	
than	randomized.		
	
Dosing	was	
titrated	versus	
randomized.		
	
Ketamine	was	not	
studied	as	
monotherapy			
Revealed	that	
dosing	response	
differed	among	
individuals,	
therefore	ketamine	
treatment	may	
need	to	be	dosed	
on	an	individual	
basis.	
Analyzed	different	
routes	of	
administration	
including	SQ,	IM,	
and	IV.		
	
	
	
Discussion:		
	
Ketamine	use	for	depression	is	most	often	limited	to	clinical	trials	because	it	is	not	currently	indicated	by	the	
Federal	Drug	Administration	for	depression.	It	is	not	a	standard	of	therapy	even	with	its	rapid	reduction	in	suicidal	
ideation	due	to	its	limitations.	Ketamine	is	given	in	IV	form	the	majority	of	the	time.	In	order	to	give	a	ketamine	
infusion,	the	safety	of	the	patient	must	be	monitored	which	includes	vital	sign	checks,	staffing	an	infusion	center,	
and	having	a	provider	oversee	the	process.	It	is	unknown	whether	a	psychiatrist	or	another	provider,	such	as	an	
anesthesiologist,	should	be	monitoring	the	patient	during	an	infusion.	Having	an	anesthesiologist	present	for	the	
infusion	would	be	beneficial,	in	that	they	are	familiar	with	ketamine	due	to	its	common	use	in	sedation;	however,	
they	may	not	be	well	equipped	to	handle	the	depressive	symptoms	and	any	acute	emerging	symptoms	from	the	
patient’s	mental	disorder	with	which	a	patient	may	present.		
	
Current	clinical	studies	focus	on	short-term	ketamine	use	and	the	potential	to	rapidly	reduce	symptoms	including	
suicidal	ideation.	This	is	important	for	providers	because	ketamine	may	have	a	future	potential	to	treat	a	patient	in	
an	emergent	setting	and	then	discharge	them	home	with	a	safety	plan	and	follow	up	for	further	therapy	and	
perhaps	continuing	infusions	in	an	outpatient	setting.	There	is	also	a	possibility	that	with	short-term	ketamine	use	
a	patient	may	be	able	to	re-titrate	their	antidepressants,	as	research	does	not	clearly	demonstrate	how	ketamine	
works	to	help	with	the	rapid	improvement	of	symptoms.		
	
Ketamine	may	also	have	other	novel	roles	in	the	treatment	of	mental	disorders	that	are	unexplored.	It	may	have	a	
role	as	an	adjunct	in	ECT	therapy.	Currently,	ketamine	is	not	regularly	used	as	the	sedative	in	ECT.	Most	often	
midazolam,	or	versed,	is	the	sedative	of	choice	in	ECT.	There	may	be	potential	for	ketamine	use	if	the	rapid	decline	
in	SI	will	allow	the	patient	to	return	to	normal	function	more	quickly	than	the	time	of	standard	ECT	therapy.		
	
Another	future	path	in	which	ketamine	can	be	evaluated	in	clinical	trials	is	analyzing	its	effects	over	a	greater	
period	of	time.	Currently,	the	majority	of	randomized	control	trials	are	ones	that	test	ketamine	over	a	short	period	
of	time	with	short	term	follow	up.	By	analyzing	the	long-term	use	and	effects	of	ketamine,	researchers	can	further	
test	if	the	efficacy	is	extended	for	a	greater	amount	of	time	and	if	the	side	effects	that	are	experienced	after	
infusion	persist.	Ketamine	has	a	history	of	abuse,	so	incorporating	close	short	and	long-term	follow-up	with	
patients	is	crucial	in	order	to	analyze	who	is	benefiting	from	ketamine	use	and	whether	it	should	be	more	widely	
available	as	a	treatment	for	refractory	depression.		
	
Limitations	to	ketamine	use	include	availability	and	cost.	As	mentioned	above,	Ketamine	is	often	given	in	IV	form,	
which	has	the	benefit	of	100%	bioavailability	and	is	the	most	widely	available.	Patients	with	severe	depression	may	
not	have	the	funds	or	insurance	to	cover	extensive	ketamine	infusions.	Mental	illness	treatment	can	be	a	costly	
lifetime	expense	with	hospitalizations,	medication	changes,	and	more	extensive	somatic	therapies.	Making	a	
treatment	that	is	sustainable	to	the	healthcare	system	and	to	patients	is	crucial	for	it	to	be	successful.		
	
Conclusion:		
	
Severe	refractory	depression	has	limited	treatment	options.	Ketamine	has	demonstrated	a	reduction	in	symptoms	
of	depression	and	suicidality	in	the	acute	setting	in	patients	with	treatment	resistant	depression	through	IV,	IM,	
SQ,	and	intranasal	administration.	Future	studies	should	focus	on	the	long-term	effects	of	ketamine,	continuing	to	
evaluate	the	efficacy	of	ketamine	on	symptoms	of	depression	and	suicidality,	especially	in	the	long	term,	and	the	
different	methods	of	drug	administration.	Future	ketamine	use	will	depend	on	accessibility	and	affordability	to	
patients	and	providers.		
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